You are using an outdated browser and your browsing experience will not be optimal. Please update to the latest version of Microsoft Edge, Google Chrome or Mozilla Firefox. Install Microsoft Edge

September 4, 2026

Surprise Inside! Thai Regulations for Food Products with Randomized Toys

Blind boxes and collectibles have become increasingly popular, driven by the excitement of not knowing which character or design will be revealed until the package is opened. While most visible in the art toy market, the same concept is also used in the food industry.

Confectionery, snacks, and other food products are sometimes sold with toys, character figures, cards, or other collectibles. A package might, for example, contain one of ten possible characters, with consumers knowing that an item is included but not which one they will receive. Some collections may also feature rare or “secret” items.

For food businesses, however, adding a randomized toy or collectible involves more than a marketing decision. The food, the nonfood item, and the randomized mechanism may each raise different regulatory considerations in Thailand.

Thai FDA Requirements for Nonfood Objects Packaged with Food

The main food regulatory consideration is Ministry of Public Health Notification No. 310 B.E. 2551 (2008), which regulates food packaged together with things or objects that are not food. Under Notification No. 310, certain nonfood objects may be packaged together with food where they fall within specified exceptions, including objects that serve the following purposes:

  • Maintaining the quality or standard of the food, such as a desiccant or oxygen absorber;
  • Serving as a seasoning or as part of food preparation, such as chili powder sachets or seasoning sachets contained in instant noodle packages; or
  • Functioning as an eating or food-preparation utensil, such as a spoon or fork included with instant noodles.

Other nonfood objects that do not fall within these categories generally should not be placed inside the food container together with the food. Where a toy, collectible, or other nonfood object is intended to be sold together with a food product, businesses should therefore carefully consider the nature of the object, how it is packaged and separated from the food, and the applicable Thai FDA requirements on a case-by-case basis.

In practice, the packaging arrangement should be assessed to ensure that the nonfood object does not create a health risk or cause consumers to mistakenly believe that it is edible. Depending on the specific packaging arrangement, this may involve placing the nonfood item outside the immediate food container, separately packaging it within the overall package, clearly separating the respective compartments, or attaching the promotional item externally to the food package.

When the Randomized Item Is a Toy

Where the nonfood item is a toy, a separate regulatory regime may also apply. Toys intended for children under 14 years of age may be subject to Thailand’s mandatory product safety requirements administered by the Thai Industrial Standards Institute (TISI), including TIS 685 on toys, depending on the characteristics and classification of the product. These requirements apply separately from the Thai FDA requirements applicable to the food and its packaging.

This is particularly relevant for imported products. A food product may need to satisfy Thai FDA requirements, while a toy included with it may separately require compliance with applicable TISI requirements.

In practice, businesses should therefore assess both the packaging arrangement under Thai FDA requirements and the toy itself under the applicable product safety requirements.

Randomized Toys, Different Values, and Other Legal Considerations

In situations where the toys are randomized, the fact that consumers do not know which toy they will receive does not, by itself, change the food regulatory analysis under Notification No. 310. Nor does the presence of randomness necessarily mean that the arrangement constitutes gambling.

However, separate legal considerations may arise depending on how the randomized mechanism is structured and marketed. One relevant factor may be the relative commercial value of the possible items. If the possible items have materially different values, the arrangement may raise different considerations than situations where the items are of broadly comparable value and the random element is primarily which character or design the consumer receives. For example, if most packages contain ordinary figures while a small number contain rare or “secret” items of substantially higher value, the difference in value may become relevant to the gambling-law analysis. Even where every consumer is guaranteed to receive an item, the element of chance may determine whether the item received is worth less than, equal to, or more than the amount paid. This may raise considerations relating to the risk of gaining or losing value under Thailand’s Gambling Act B.E. 2478 (1935), as the nature and value of the possible items, whether any additional prize or premium is offered by chance, and the overall structure of the promotion may also be relevant.

A related issue may arise where additional prizes or premiums are randomly included with the purchased product. Depending on the structure, this may fall within the provisions of the Gambling Act concerning the offering of premiums or prizes by chance, for which prior permission may be required.

The treatment of claw machines provides a useful comparison. Under the Gambling Act, as amended, certain amusement machines capable of producing a win-or-lose outcome may fall within the gambling regulatory framework. In a conventional claw-machine arrangement, a player pays for each attempt but may receive nothing if unsuccessful. The outcome therefore determines whether the player receives an item at all.

When assessing the regulatory implications of randomized items, the analysis should consider the overall structure of the transaction, including whether the consumer is guaranteed to receive an item, the relative value of the possible items, the role of chance in determining the outcome, and how the promotion is structured and marketed. Whether a particular arrangement raises issues under the Gambling Act will ultimately depend on its specific circumstances and should be assessed separately on a case-by-case basis.

One Product, Multiple Regulatory Considerations

A food product containing a randomized toy may appear to consumers as a single product, but businesses may need to consider several regulatory layers: Thai FDA requirements for the food and the packaging of a nonfood object with it, TISI safety and compliance requirements applicable to the toy, and other applicable laws that may be relevant to the structure of any randomized or chance-based promotional mechanism.

Each regime addresses a different regulatory issue. Compliance with Thai FDA requirements, for example, has no bearing on whether the toy complies with TISI requirements or whether the promotional mechanism raises issues under other laws.

Key Takeaways for Food Businesses

As food brands increasingly use collectibles, character collaborations, and blind-box-style concepts, these regulatory considerations should be addressed early in product development.

For food products containing randomized toys, businesses should consider what the nonfood item is, how it is packaged with and separated from the food, whether separate product standards apply to the toy, and how any randomized mechanism is structured and promoted.

Where the possible collectibles have materially different relative commercial values, additional legal review may also be appropriate, particularly where the promotion emphasizes the chance of obtaining a rare or high-value item.

Ultimately, what appears to consumers as a simple “surprise inside” may involve several regulatory layers. Identifying these considerations early in product development can help food businesses address potential regulatory issues before the product reaches the Thai market.

RELATED INSIGHTS​ 

July 10, 2023
On June 30, 2023, the Ministry of Health of Vietnam issued Circular No. 14/2023/TT-BYT stipulating the process and procedure for building bidding package prices for procurement of goods and services in the field of medical devices at public health facilities (“Circular 14”). Circular 14 took effect on July 1, 2023, and will be valid through the end of 2023. Circular 14 applies to the procurement of medical devices/equipment and their accessories, spare parts, and supplies, as well as related services of repair, maintenance, inspection, and calibration. Under Circular 14, there are three methods of determining the price of bidding packages: Collecting quotations provided by suppliers of goods and services in the field of medical devices. Surveying the winning bid prices of similar goods and services on the national bidding network system (https://muasamcong.gov.vn). Using the results of price appraisal of a competent state agency that conducts price appraisal, or a specialized price appraisal enterprise. Method (i) must be used first; the two remaining methods can be applied only after method (i) has been unsuccessful. If the investor/procuring entity uses two or more methods to determine the price of bidding packages, it can select the highest price that is suitable to its financial capacity and professional requirements. Circular 14 further sets out the specific step-by-step process to build prices for procuring products and services in the field of medical devices/equipment. Transitional Provision For bidding packages that have already approved a contractor selection plan before July 1, 2023, the approved contractor selection plan will be followed. For bidding packages for which a contractor selection plan has been submitted by the investor/procuring entity but the plan has not yet been approved, the competent person can decide on the approval of the submitted plan or can request the investor/procuring entity to rebuild the bidding
July 4, 2023
Practitioners from Tilleke & Gibbins’ Vietnam offices contributed content for the latest edition of the Practical Law Life Sciences Global Guide. The guide provides a comparative overview, in Q&A format, of laws and regulations on pharmaceuticals, medical devices, and other life sciences products in dozens of jurisdictions around the world. The Life Sciences Global Guide is divided into two sections: Regulation (see more details here) and Commercialization, which covers the following topics: Overview of the life sciences sector Pricing, government funding, and reimbursement: National health care system, price regulation and reimbursement Distribution and sale Cross-border trade and parallel imports Advertising to the public and engagement with patient organizations Advertising to healthcare professionals and organizations: Gifts and incentives and transparency and disclosure Patents: Conditions for patentability, registration, length of protection, infringement, international treaties Trademarks: Requirements, registration Competition law issues: Authorities and legislation, commercial contracts and competition law, licensing approvals and formalities Product liability: Regulators, medicinal product liability law, liable partners, defenses, product liability claims, remedies Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. The full “Life Sciences Commercialization in Vietnam” section can be found on the Practical Law website.
July 4, 2023
Practitioners from Tilleke & Gibbins’ Vietnam offices contributed content for the latest edition of the Practical Law Life Sciences Global Guide. The guide provides a comparative overview, in Q&A format, of laws and regulations on pharmaceuticals, medical devices, and other life sciences products in dozens of jurisdictions around the world. The Life Sciences Global Guide is divided into two sections: Commercialization (see more details here) and Regulation, which covers the following topics: Pharmaceuticals: Laws and regulatory authorities Clinical trials: Legal, regulatory, and procedural requirements Manufacturing and distribution Marketing: Authorization for marketing medicinal products, monitoring compliance and penalties, pharmacovigilance and other commitments, foreign marketing authorizations Data privacy Packaging, labeling, and tracking Biological medicines Medical devices: Legislation and regulatory authorities, definition and classification Healthcare IT Combination products and borderlines Natural health products Recent developments and reform proposals Practical Law, produced by Thomson Reuters, is the world’s leading legal know-how resource for business lawyers, publishing a huge range of guides covering hundreds of jurisdictions and practice areas. The full “Life Sciences Regulation in Vietnam” section can be found on the Practical Law website.
June 1, 2023
Life sciences specialists from Tilleke & Gibbins have supplied the Thailand and Vietnam contributions to the International Bar Association (IBA) Healthcare and Life Sciences Law Committee’s global telemedicine survey. The survey, spanning 54 jurisdictions worldwide, functions as a comparative legal guide on the provision of telemedicine and related products and services. It offers practitioners and industry users access to relevant rules and regulations, addressing key aspects such as regulation, data privacy, liability, and recent developments in telemedicine. Telemedicine has emerged as a transformative force in healthcare, revolutionizing the way medical services are accessed and delivered. As in many other jurisdictions, telemedicine has gained prevalence in Thailand and Vietnam, as it enables patients to remotely consult with healthcare professionals, access diagnostic services, and receive timely medical advice while minimizing physical contact. As the global healthcare landscape continues to evolve, understanding the legal and regulatory aspects of telemedicine becomes paramount, making initiatives like the IBA’s telemedicine survey vital for practitioners and industry stakeholders. The IBA is a globally recognized organization that brings together legal professionals and bar associations from around the world, and its Healthcare and Life Sciences Law Committee plays a crucial role in addressing legal issues and developments in the healthcare industry. The complete surveys for Thailand and Vietnam­—and the 52 other participating jurisdictions—are available on the IBA website.